---
title: "IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294493218.md"
description: "IDEAYA Biosciences granted 260,200 inducement stock options to 14 new employees on July 30, 2026. The options carry an exercise price of $36.4 per share, aligning with the Nasdaq closing price. These awards have a 10-year term, with vesting scheduled at 25% after one year and monthly thereafter over the next three years."
datetime: "2026-07-31T10:00:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294493218.md)
  - [en](https://longbridge.com/en/news/294493218.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294493218.md)
generator: "portal-rs"
---

# IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per share

-   IDEAYA Biosciences issued inducement stock options covering 260,200 shares to 14 newly hired employees on July 30, 2026. \* Options carry an exercise price of USD 36.4 per share, matching the stock’s Nasdaq close on the grant date. \* Awards run for 10 years; vesting is 25% after one year, then monthly over the next three years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607310600PR\_NEWS\_USPR\_\_\_\_\_FL16456) on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)

## Related News & Research

- [IDYA: Darovasertib and key pipeline assets advance toward major regulatory and clinical milestones](https://longbridge.com/en/news/298363053.md)
- [IDEAYA targets year-end 2026 start for Phase 3 IDE849 trial in extensive-stage small cell lung cancer](https://longbridge.com/en/news/297497016.md)
- [Syndax grants stock options for 175,000 shares to 19 new employees under inducement plan](https://longbridge.com/en/news/298070858.md)
- [Avalo Therapeutics grants 78,000 inducement stock options priced at $19.34 per share](https://longbridge.com/en/news/298071367.md)
- [Taysha Gene Therapies grants new hires 314,000 RSUs, 92,400 options at $5.7 strike](https://longbridge.com/en/news/298034947.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**